JP2024530315A - Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法 - Google Patents

Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法 Download PDF

Info

Publication number
JP2024530315A
JP2024530315A JP2024513277A JP2024513277A JP2024530315A JP 2024530315 A JP2024530315 A JP 2024530315A JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024530315 A JP2024530315 A JP 2024530315A
Authority
JP
Japan
Prior art keywords
crystalline form
compound
ray powder
powder diffraction
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530315A5 (https=
Inventor
ユ、デシェン
シ、ゴォンイン
シュエ、ハイ
グオ、ユンハン
Original Assignee
ベイジーン スウィッツァーランド ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジーン スウィッツァーランド ゲーエムベーハー filed Critical ベイジーン スウィッツァーランド ゲーエムベーハー
Publication of JP2024530315A publication Critical patent/JP2024530315A/ja
Publication of JP2024530315A5 publication Critical patent/JP2024530315A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024513277A 2021-08-31 2022-08-31 Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法 Pending JP2024530315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/115718 2021-08-31
CN2021115718 2021-08-31
PCT/CN2022/116084 WO2023030363A1 (en) 2021-08-31 2022-08-31 Solid forms of bcl-2 inhibitors, method of preparation, and use thereof

Publications (2)

Publication Number Publication Date
JP2024530315A true JP2024530315A (ja) 2024-08-16
JP2024530315A5 JP2024530315A5 (https=) 2025-09-03

Family

ID=85410866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513277A Pending JP2024530315A (ja) 2021-08-31 2022-08-31 Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法

Country Status (11)

Country Link
US (1) US20240317743A1 (https=)
EP (1) EP4396180A4 (https=)
JP (1) JP2024530315A (https=)
KR (1) KR20240054327A (https=)
CN (1) CN118215660A (https=)
AU (1) AU2022336557A1 (https=)
CA (1) CA3230314A1 (https=)
IL (1) IL311106A (https=)
MX (1) MX2024002465A (https=)
TW (1) TW202328125A (https=)
WO (1) WO2023030363A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
WO2026002056A1 (en) 2024-06-26 2026-01-02 Beone Pharmaceutical (Suzhou) Co., Ltd. A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138588A2 (en) * 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2668180B1 (en) * 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
SG11202009933WA (en) * 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Also Published As

Publication number Publication date
WO2023030363A1 (en) 2023-03-09
CA3230314A1 (en) 2023-03-09
KR20240054327A (ko) 2024-04-25
CN118215660A (zh) 2024-06-18
AU2022336557A1 (en) 2024-03-21
EP4396180A4 (en) 2025-07-09
TW202328125A (zh) 2023-07-16
EP4396180A1 (en) 2024-07-10
US20240317743A1 (en) 2024-09-26
IL311106A (en) 2024-04-01
MX2024002465A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
TWI526440B (zh) ３－（２，６－二氯－３，５－二甲氧基－苯基）－１－｛（６－［４－（４－乙基－六氫吡－１－基）－苯胺基］－吡啶－４－基｝－１－甲基尿素之結晶型及其鹽
KR102618114B1 (ko) 이브루티닙과 카복실산의 공결정체
KR20260041111A (ko) 아다그라시브 염의 결정질 형태
US20140343087A1 (en) Crystalline Forms of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
CN108779126A (zh) 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物的结晶形式
JP7314319B2 (ja) Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
US20240317743A1 (en) Solid Forms of BCL-2 Inhibitors, Method of Preparation, and Use Thereof
KR20210119444A (ko) 7-사이클로펜틸-2-(5-피페라진-1-일-피리딘-2-일아미노)-7h-피롤로[2,3-d]피리미딘-6-카복실산 디메틸아미드의 석신산염의 신규한 결정질 형태
ES2814499T3 (es) Formas en estado sólido de sales de Nilotinib
JP2016512518A (ja) ベムラフェニブ塩酸塩の固体形態
WO2018076117A1 (en) Novel salts of nilotinib and crystalline forms thereof
US20190016718A1 (en) Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
CN114026088A (zh) Jak2抑制剂的结晶形式
JP6656505B2 (ja) オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法
KR20060080817A (ko) 시부트라민의 디카복실산염
HK40106793A (zh) Bcl-2抑制剂的固体形式、其制备方法及用途
TWI809330B (zh) Cdk9抑制劑的多晶型物及其製法和用途
TWI846516B (zh) Cdk9抑制劑的多晶型物及其製法和用途
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
KR20240146734A (ko) 피마살탄의 신규 염 및 이의 제조방법
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
HK40111611A (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250826